Investors Face August Deadline in ADMA Biologics Securities Lawsuit

The lawsuit contends that throughout the specified period, ADMA Biologics issued materially false or misleading statements to the market. Specifically, the complaint alleges the company engaged in undisclosed related party transactions and utilized channel stuffing practices to artificially inflate revenue figures. Furthermore, plaintiffs claim the firm lacked sufficient internal controls, rendering its public statements about business operations and financial prospects baseless.

Investors who incurred losses during the class period may be eligible for compensation through a contingency fee arrangement. While a lawsuit has been filed, no class has been certified, meaning shareholders are not currently represented by counsel unless they choose to retain their own. Those interested in serving as lead plaintiff must move the court by the August 10 deadline, though investors may also choose to remain absent class members and await potential future recovery without taking active roles in the litigation.